Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World REKOVELLE study targets IVF success in asian women

NCT ID NCT06561958

Ongoing Knowledge-focused Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 1,500 Asian women using REKOVELLE for the first time during IVF to see how well it works in everyday medical practice. Researchers will track live birth rates and how the drug is used. The goal is to understand its real-world effectiveness and safety for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
REKOVELLE (a hormone drug for ovarian stimulation)
What this could lead to
If successful, this study could confirm that REKOVELLE is effective and safe for Asian women, potentially improving IVF success rates in this population.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only gathers real-world data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFERTILITY

Contacts and locations

Locations

  • Ferring Investigational Site

    Chiba, Chiba, 2610023, Japan

  • Ferring Investigational Site

    Fukuoka, Fukuoka, 8120013, Japan

  • Ferring Investigational Site

    Kitakyushu, Fukuoka, 8070825, Japan

  • Ferring Investigational Site

    Takasaki, Gunma, 3700841, Japan

  • Ferring Investigational Site

    Hiroshima, Hiroshima, 7320822, Japan

  • Ferring Investigational Site

    Bunkyō City, Japan, 1130033, Japan

  • Ferring Investigational Site

    Tokyo, Tokyo, 1600023, Japan

  • Ferring Investigational Site

    Hiroshima, 7300035, Japan

  • Ferring Investigational Site

    Hokkaido, 0600003, Japan

  • Ferring Investigational Site

    Hyōgo, 6500021, Japan

  • Ferring Investigational Site

    Osaka, 5300011, Japan

  • Ferring Investigational Site

    Osaka, 5500015, Japan

  • Ferring Investigational Site

    Saitama, 3540035, Japan

  • Ferring Investigational Site

    Busan, Busan, 49241, South Korea

  • Ferring Investigational Site

    Daegu, Daegu, 41910, South Korea

  • Ferring Investigational Site

    Seongnam-si, Seongnam, 13496, South Korea

  • Ferring Investigational Site

    Busan, 47245, South Korea

  • Ferring Investigational Site

    Tainan, Tainan, 70403, Taiwan

  • Ferring Investigational Site

    Tainan, Tainan, 71004, Taiwan

  • Ferring Investigational Site

    Taoyuan, Taoyuan, 333, Taiwan

  • Ferring Investigational Site

    Taichung, 406, Taiwan

  • Ferring Investigational Site

    Taipei, 100225, Taiwan

  • Ferring Investigational Site

    Taipei, 110, Taiwan

  • Ferring Investigational Site

    Bangkok, 10700, Thailand

  • Ferring Investigational Site

    Hanoi, Hanoi, 100000, Vietnam

  • Ferring Investigational Site

    Ho Chi Minh City, Ho Chi Minh City, 700000, Vietnam

  • Ferring Investigational Site

    Ho Chi Minh City, Ho Chi Minh City, Vietnam

  • Ferring Investigational Site

    Huế, Huế, 49000, Vietnam

  • Maria Fertility Hospital

    Seoul, 02586, South Korea

  • Naresuan University Hospital

    Phitsanulok, Muang, 65000, Thailand

  • Ramathibodi Hospital

    Bangkok, Ratchathewi, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.